PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
€91.50
Adamax Ireland – Buy Online | In Stock & Ready to Ship
Buy Adamax in Ireland with fast shipping and guaranteed ≥99% purity — verified with COA and HPLC documentation. A trusted choice for peptides Ireland research teams rely on, with no customs delays or international wait times. Whether you’re searching for Adamax Ireland suppliers or looking to buy peptides Ireland-wide, we have you covered. Irish research teams can count on consistent stock, rapid fulfilment and full batch documentation every time.
For research use only. Not intended for human or veterinary use.
Adamax (Desmopressin with adamantane modification) — also referenced in research contexts as a next-generation vasopressin receptor-targeting peptide — is one of the most specifically engineered synthetic vasopressin analogues available to laboratories in Ireland, combining selective V1b/V2 receptor engagement with enhanced metabolic stability through adamantane structural modification to produce a research compound of significant interest for studying vasopressin receptor pharmacology, HPA axis stress response regulation, memory consolidation and cognitive biology, renal water homeostasis mechanisms, and the intersection of neuropeptide signalling with neuroendocrine stress circuitry. Researchers and institutions across Ireland can source verified, research-grade Adamax directly from our Irish peptide supply, with domestic-speed dispatch and complete batch documentation included.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA) Included
✅ Sterile Lyophilised Powder | GMP Manufactured
✅ Fast Dispatch to Ireland | Peptides Ireland Stock
Adamax is a synthetic vasopressin analogue peptide incorporating an adamantane moiety — a cage-shaped polycyclic hydrocarbon structure widely used in medicinal chemistry to enhance compound metabolic stability, membrane permeability, and receptor binding geometry. In the context of vasopressin analogue research, the adamantane modification is applied to the neuropeptide scaffold to improve resistance against enzymatic degradation — particularly by vasopressinase and other peptidases that rapidly inactivate native vasopressin and limit its research utility in extended protocols — while preserving or enhancing receptor binding affinity at the vasopressin receptor subtypes most relevant to the research application.
Vasopressin (Arginine Vasopressin, AVP) is a nine amino acid cyclic neuropeptide — structurally closely related to oxytocin, differing by only two amino acids — produced in the hypothalamic paraventricular nucleus (PVN) and supraoptic nucleus (SON) and acting through three G-protein coupled receptor subtypes: V1a receptors mediating cardiovascular and social behaviour effects, V1b receptors mediating HPA axis stress response regulation through pituitary ACTH release stimulation, and V2 receptors mediating renal water reabsorption and antidiuretic effects. The precise receptor subtype engagement profile of Adamax — determined by the specific adamantane modification position and the peptide backbone sequence — makes it a targeted research tool for studying specific vasopressin receptor subtype biology with improved pharmacokinetic characteristics compared to native AVP.
The adamantane modification strategy in neuropeptide research reflects a broader medicinal chemistry approach — adding the bulky lipophilic adamantane cage to peptide structures to simultaneously improve metabolic stability, enhance membrane penetration for central nervous system research applications, and in some cases fine-tune receptor subtype selectivity through steric effects on receptor binding pocket interactions. These properties make Adamax-type vasopressin analogues particularly relevant for pre-clinical research examining vasopressin receptor pharmacology in intact biological systems where native AVP’s short half-life limits experimental design options.
In controlled laboratory and pre-clinical settings, Adamax research is centred on its vasopressin receptor engagement with the pharmacokinetic advantages conferred by adamantane modification. Research applications include studying vasopressin receptor pharmacology and subtype selectivity, V1b receptor biology and HPA axis stress response regulation, ACTH release stimulation and corticotroph cell biology, V2 receptor pharmacology and renal water homeostasis, memory consolidation and cognitive function through vasopressin pathway research, hypothalamic-pituitary-adrenal axis regulation mechanisms, stress neuroendocrinology and CRH-vasopressin interaction biology, social behaviour and V1a receptor pathway comparative studies, adamantane modification effects on peptide metabolic stability, comparative vasopressin analogue pharmacology, central nervous system vasopressin signalling and neuropeptide biology, anxiety and depression-related HPA axis dysregulation research, antidiuretic pathway and aquaporin regulation mechanisms, neuropeptide structure-activity relationship investigations, and oxytocin-vasopressin receptor cross-reactivity research.
Its adamantane-enhanced metabolic stability — providing extended research utility in biological systems compared to native AVP — makes Adamax a practical research tool for studying vasopressin receptor biology in extended pre-clinical protocols requiring sustained receptor engagement. All applications are for research use only.
Adamantane modification research in neuropeptide chemistry has characterised how the bulky polycyclic adamantane cage influences peptide metabolic stability — with studies documenting significantly enhanced resistance to vasopressinase and other peptidase-mediated degradation compared to native AVP and unmodified vasopressin analogues. These stability improvements translate directly to extended biological activity windows in research models — a critical practical advantage for pre-clinical studies requiring consistent vasopressin receptor engagement across multi-hour or multi-day experimental protocols.
Vasopressin receptor pharmacology research has used adamantane-modified analogues to examine how structural modification influences receptor subtype binding profiles — with studies characterising changes in V1a, V1b, and V2 receptor affinity resulting from adamantane incorporation at different positions in the vasopressin scaffold. These SAR studies have contributed to understanding of how bulky lipophilic modifications influence vasopressin receptor pocket accommodation and informed rational design of improved vasopressin analogue research tools.
HPA axis stress research has examined vasopressin receptor biology as a central component of stress neuroendocrinology — with studies characterising V1b receptor-mediated ACTH release from pituitary corticotroph cells alongside CRH as the two primary hypothalamic drivers of HPA axis activation. Research using vasopressin analogues with improved metabolic stability has provided insights into how vasopressin’s contribution to HPA axis activation interacts with CRH under acute and chronic stress conditions — making enhanced-stability vasopressin analogues important research tools for extended pre-clinical stress models.
Memory and cognitive biology research has drawn on the well-established connection between vasopressin signalling and memory consolidation — with studies documenting effects of vasopressin receptor activation on hippocampal function, long-term potentiation, and spatial memory parameters in pre-clinical models. Vasopressin analogues with improved metabolic stability provide more consistent receptor engagement in cognitive research protocols — enabling cleaner experimental designs for studying how vasopressin receptor pharmacology influences memory biology.
Neuropeptide medicinal chemistry research has used adamantane-modified peptides as a platform for studying how cage hydrocarbon modifications influence the physicochemical and pharmacological properties of bioactive peptides — with findings applicable across multiple neuropeptide classes beyond vasopressin. These structural biology studies have established adamantane modification as a validated research strategy for improving neuropeptide research tool practicality in extended pre-clinical protocols.
| Feature | Adamax | Native AVP (Vasopressin) | Desmopressin (DDAVP) | Terlipressin | SSR149415 | Oxytocin |
|---|---|---|---|---|---|---|
| Type | Adamantane-modified vasopressin analogue | Endogenous nonapeptide | V2-selective analogue | V1a-selective prodrug | V1b selective antagonist | Endogenous nonapeptide |
| Primary Receptors | V1b/V2 — profile dependent on modification | V1a + V1b + V2 | V2 selective | V1a selective | V1b selective antagonist | OXTR (+ V1a/V1b cross) |
| Half-Life | Extended vs AVP — adamantane stability | ~minutes | ~1–2 hours | ~6 hours | Variable | ~minutes |
| Key Research Focus | Vasopressin pharmacology / HPA axis / metabolic stability | Reference vasopressin biology | Renal water homeostasis / V2 pharmacology | Cardiovascular vasopressin research | HPA axis / stress research | Social behaviour / reproduction |
| Research Profile | Growing | Extensively studied | Extensively studied | Well-documented | Well-documented | Extensively studied |
| Parameter | Detail |
|---|---|
| Name | Adamax |
| Type | Synthetic Adamantane-Modified Vasopressin Analogue — Research Grade |
| Modification | Adamantane moiety — metabolic stability enhancement |
| Receptor Targets | Vasopressin receptor subtypes — V1b/V2 profile |
| Key Research Distinction | Enhanced metabolic stability versus native AVP through adamantane modification — extended biological activity window for pre-clinical vasopressin receptor research protocols |
| Primary Research Areas | Vasopressin receptor pharmacology / HPA axis stress neuroendocrinology / memory and cognitive biology / renal water homeostasis / CRH-vasopressin interaction / comparative vasopressin analogue SAR |
| Purity | ≥99% HPLC & MS Verified |
| Form | Sterile Lyophilised Powder |
| Solubility | Sterile water or suitable laboratory buffer |
| Storage (Powder) | -20°C, protected from light and moisture |
| Storage (Reconstituted) | -80°C in aliquots — minimise freeze-thaw cycles |
| Manufacturing | GMP Manufactured |
| Intended Use | Research use only |
Allow the vial to reach room temperature before opening. Add sterile water or appropriate laboratory buffer slowly down the vial wall and swirl gently without shaking. Prepare at your protocol’s required concentration. The adamantane modification provides enhanced proteolytic stability compared to native AVP — however standard peptide handling protocols should be followed to preserve biological activity. Aliquot and store at -80°C to minimise freeze-thaw degradation and maintain peptide integrity between experimental sessions.
Every order of Adamax in Ireland includes:
✅ Batch-Specific Certificate of Analysis (CoA)
✅ HPLC Chromatogram
✅ Mass Spectrometry Confirmation
✅ Sterility & Endotoxin Testing Report
✅ Reconstitution Protocol
✅ Technical Research Support
Yes — we supply research-grade Adamax to researchers and institutions across Ireland with fast dispatch and full batch documentation. Supplied strictly for laboratory research purposes only.
Adamantane is a cage-shaped polycyclic hydrocarbon — a compact, rigid, and highly symmetric structure widely adopted in medicinal chemistry as a metabolic stability-enhancing modification for bioactive compounds. When incorporated into peptide research tools, adamantane contributes improved resistance against enzymatic degradation by creating steric hindrance around cleavage sites and introducing lipophilic bulk that can enhance membrane permeability for CNS research applications. In vasopressin analogue research specifically, adamantane modification addresses native AVP’s very short half-life — enabling extended biological activity windows that allow more practical pre-clinical research protocol designs without compromising receptor engagement specificity.
The three vasopressin receptor subtypes have distinct tissue distributions and biological functions. V1a receptors are expressed in vascular smooth muscle, liver, and brain — mediating cardiovascular vasoconstriction and social behaviour modulation, with cross-reactivity with oxytocin receptors relevant to social neuroscience research. V1b receptors are expressed primarily in pituitary corticotroph cells — mediating ACTH release stimulation as the second major HPA axis activator alongside CRH, making V1b pharmacology central to stress neuroendocrinology research. V2 receptors are expressed in renal collecting duct cells — mediating aquaporin-2 insertion and water reabsorption, making V2 pharmacology central to water homeostasis and antidiuretic research.
The HPA axis stress response is driven by two primary hypothalamic signals — CRH and vasopressin — acting synergistically on pituitary V1b receptors to stimulate ACTH release, which in turn drives adrenal cortisol production. Research has established that vasopressin’s V1b-mediated contribution to HPA axis activation becomes increasingly significant under chronic stress conditions — with V1b receptor upregulation amplifying pituitary sensitivity to vasopressin as stress chronifies. Adamax-type vasopressin analogues with improved metabolic stability enable more consistent V1b receptor engagement in chronic stress research protocols — providing research tools better suited to studying vasopressin’s contribution to HPA axis dysregulation in extended pre-clinical stress models.
Desmopressin (DDAVP) is the most widely used vasopressin analogue in research and clinical settings — a V2-selective analogue with minimal V1a activity, primarily used for studying renal water homeostasis and antidiuretic biology. Adamax differs in its adamantane modification strategy and receptor subtype engagement profile — providing a research tool for studying vasopressin receptor pharmacology with enhanced metabolic stability characteristics. While Desmopressin’s V2 selectivity makes it the reference compound for renal vasopressin biology, Adamax-type modifications address the broader vasopressin receptor subtype pharmacology space with improved stability — making the two compounds complementary rather than competing research tools.
Vasopressin has a well-documented role in memory consolidation and cognitive function — with research characterising vasopressin receptor expression in hippocampal and cortical regions involved in memory formation and retrieval. Studies using vasopressin analogues have examined effects on long-term potentiation, spatial memory parameters, and social recognition memory in pre-clinical models — with vasopressin receptor activation consistently associated with enhanced memory consolidation across multiple learning paradigms. Metabolically stable vasopressin analogues like Adamax provide improved research tools for studying vasopressin’s cognitive effects in extended protocols — enabling cleaner experimental designs for examining how sustained vasopressin receptor engagement influences hippocampal-dependent memory biology.
≥99% purity is essential for vasopressin receptor pharmacology studies, HPA axis stress research, memory consolidation paradigms, and comparative vasopressin analogue research — where impurities including unmodified vasopressin fragments or incompletely adamantylated species would show altered receptor subtype selectivity and confound dose-response characterisation. All Adamax Ireland stock is verified to ≥99% purity by HPLC and mass spectrometry with identity confirmation.
Orders are dispatched promptly from Irish stock via tracked courier. Domestic Irish delivery is fast with no customs delays or international transit times — packaging is designed to maintain peptide stability and integrity throughout dispatch.
Adamax is supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. This product is not intended for human consumption, self-administration, or any therapeutic application. It must be handled by qualified researchers in compliance with applicable Irish and EU regulations and institutional ethics guidelines. By purchasing, you confirm that this compound will be used solely for approved in vitro or pre-clinical research purposes.
Receive News
